Kate M. Warde

Kate M. Warde

Auto-generated profile, based on publicly available information

Kate M. Warde

Huntsman Cancer Institute, University of Utah 23 , Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
KWKate M. Warde
Kate M. Warde
LSLorenzo J. Smith
Lorenzo J. Smith
LLLihua Liu
Lihua Liu
CSChris J. Stubben
Chris J. Stubben
BLBrian K. Lohman
Brian K. Lohman
KBKaitlin J. Basham
Kaitlin J. Basham

20 July 2023 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
KWKate M Warde
Kate M Warde
LSLorenzo J Smith
Lorenzo J Smith
KBKaitlin J Basham
Kaitlin J Basham
Aging is characterized by a gradual decline in physiological function. This process affects all organs including the adrenal cortex, which normally functions to produce essential steroid hormones including mineralocorticoids, glucocorticoids, and androgens. With increasing age, features such as reduced adrenal cortex size, altered zonation, and increased myeloid immune cell infiltration substantially alter the structure and function of the adrenal cortex. Many of these hallmark features of adrenal cortex aging occur both in males and females, yet are more enhanced in males. Hormonally, a substantial reduction in adrenal androgens is a key feature of aging, which is accompanied by modest changes in aldosterone and cortisol. These hormonal changes are associated with various pathological consequences including impaired immune responses, decreased bone health, and accelerated age-related diseases. One of the most notable changes with adrenal aging is the increased incidence of adrenal tumors, which is sex dimorphic with a higher prevalence in females. Increased adrenal tumorigenesis with age is likely driven by both an increase in genetic mutations as well as remodeling of the tissue microenvironment. Novel antiaging strategies offer a promising avenue to mitigate adrenal aging and alleviate age-associated pathologies, including adrenal tumors.

1 June 2020 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
KWKate M Warde
Kate M Warde
ESErik Schoenmakers
Erik Schoenmakers
EMEduardo Ribes Martinez
Eduardo Ribes Martinez
YLYi Jan Lim
Yi Jan Lim
MLMaeve Leonard
Maeve Leonard
MDMichael Conall Dennedy
Michael Conall Dennedy
Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with a poor outcome largely due to limited treatment options. Here, we propose a novel therapeutic approach through modulating intracellular free cholesterol via the liver X receptor alpha (LXRα) in combination with current first-line pharmacotherapy, mitotane. H295R and MUC-1 ACC cell lines were pretreated with LXRα inhibitors in combination with mitotane. In H295R, mitotane (20, 40 and 50 µM) induced dose-dependent cell death; however, in MUC-1, this only occurred at a supratherapeutic concentration (200 µM). LXRα inhibition potentiated mitotane-induced cytotoxicity in both cell lines. This was confirmed through use of the CompuSyn model which showed moderate pharmacological synergism and was indicative of apoptotic cell death via an increase in annexinV and cleaved-caspase 3 expression. Inhibition of LXRα was confirmed through downregulation of cholesterol efflux pumps ABCA1 and ABCG1; however, combination treatment with mitotane attenuated this effect. Intracellular free-cholesterol levels were associated with increased cytotoxicity in H295R (r2 = 0.5210) and MUC-1 (r2 = 0.9299) cells. While both cell lines exhibited similar levels of free cholesterol at baseline, H295R were cholesterol ester rich, whereas MUC-1 were cholesterol ester poor. We highlight the importance of LXRα mediated cholesterol metabolism in the management of ACC, drawing attention to its role in the therapeutics of mitotane sensitive tumours. We also demonstrate significant differences in cholesterol storage between mitotane sensitive and resistant disease.

7 July 2022 in Endocrinology
Verified
Journal Article
Open access
PDF file
KWKate M Warde
Kate M Warde
YLYi Jan Lim
Yi Jan Lim
EMEduardo Ribes Martinez
Eduardo Ribes Martinez
FBFelix Beuschlein
Felix Beuschlein
POPaula O'Shea
Paula O'Shea
MDMichael Conall Dennedy
Michael Conall Dennedy
Introduction: Adrenocortical carcinoma (ACC) is a rare aggressive cancer with low overall survival. Adjuvant mitotane improves survival but is limited by poor response rates and resistance. Mitotane’s efficacy is attributed to the accumulation of toxic free cholesterol, predominantly through cholesterol storage inhibition. However, targeting this pathway has proven unsuccessful. We hypothesize that mitotane-induced free-cholesterol accumulation is also mediated through enhanced breakdown of lipid droplets. Methodology: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using specific BODIPY dyes. Protein expression was evaluated by immunoblotting and flow cytometry. Cell viability was measured by quantifying propidium iodide-positive cells following mitotane treatment and pharmacological inhibitors of lipolysis. Results: H295R and MUC-1 cells demonstrated similar neutral lipid droplet numbers at baseline. However, evaluation of lipid machinery demonstrated distinct profiles in each model. Analysis of intracellular lipid droplet content showed H295R cells preferentially store cholesteryl esters, whereas MUC-1 cells store triacylglycerol. Decreased lipid droplets were associated with increased lipolysis in H295R and in MUC-1 at toxic mitotane concentrations. Pharmacological inhibition of lipolysis attenuated mitotane-induced toxicity in both models. Conclusion: We highlight that lipid droplet breakdown and activation of lipolysis represent a putative additional mechanism for mitotane-induced cytotoxicity in ACC. Further understanding of cholesterol and lipids in ACC offers potential novel therapeutic exploitation, especially in mitotane-resistant disease.

12 October 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
SRSimon F. Roy
Simon F. Roy
AFAmy C. Fan
Amy C. Fan
KBKelsey B. Bennion
Kelsey B. Bennion
MCMehdi Chaib
Mehdi Chaib
HCHokyung K. Chung
Hokyung K. Chung
NHNir Hacohen
Nir Hacohen
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.